BACKGROUND: Previous studies demonstrated substantial economic and comorbidity burden associated with psoriasis (PsO) before biologics were available. Biologics have changed PsO treatment paradigms and potentially improved patient outcomes. There is a need to reassess the economic and comorbidity burden of PsO in the biologic era.
Sample Selection
Patients with at least 2 diagnoses of PsO (ICD-9-CM code 696.1) on different dates from January 1, 2007, to March 31, 2012 , were selected into the PsO cohort. The index date was randomly selected among potential calendar dates after the first PsO diagnosis that met the following criteria: (a) patients were continuously enrolled for 12 months (study period) after a potential index date, and (b) patients were aged 18-64 years as of a potential index date. Patient enrollment periods covered by health maintenance organizations (HMOs) were excluded due to incomplete cost information in the database. Moderateto-severe PsO patients were further identified as those who received at least 1 nontopical systemic therapy (see Appendix A for Generic Product Identifier [GPI] codes, available in online article) or phototherapy (see Appendix B for CPT codes, available in online article) during the study period.
Patients free of PsO (ICD-9-CM code 696.1) and PsA (ICD-9-CM code 696.0) throughout the entire claims history (i.e., January 1, 1999-March 31, 2012) were included as control candidates and matched 1:1 with moderate-to-severe PsO patients based on age, gender, and geographic region as of the index date using the exact matching technique. Specifically, for each moderate-to-severe PsO patient, control candidates were assigned the same index date and had to have the same age, gender, and geographic region as of the index date. Control candidates were further required to be continuously enrolled for 12 months following the index date (excluding enrollment periods covered by HMOs). One control patient was selected among all control candidates meeting these criteria. If a patient was selected as a control for a PsO patient, the patient was removed from the control candidates for the next PsO patients.
Patient Characteristics and Outcomes
Patient characteristics as of the index date included demographics (age, gender, and geographic region); insurance type; and calendar year of index date. Two types of comorbidities, selected and common comorbidities, and other comorbid medical conditions were identified based on the ICD-9-CM codes in either the primary or secondary diagnosis code during the 12-month study period. Selected and common comorbidities (see Appendix C, available in online article) included PsA, hyperlipidemia, hypertension, diabetes, obesity, coronary heart disease, cerebrovascular disease (stroke), peripheral vascular disease, depression, anxiety, rheumatoid arthritis, Crohn's disease or ulcerative colitis, multiple sclerosis, skin cancer, lymphoma, other autoimmune disorders, and other malignancies. Other comorbid medical conditions (see Appendix D, available in online article) included all components of the Charlson Comorbidity Index (CCI) except for those included in the selected and common comorbidities already mentioned. A modified CCI was calculated based on these comorbidities. 29 Due to its chronic nature and comorbidities, PsO incurs substantial economic burden to society. 18 In 2006, the total U.S. direct costs associated with PsO were estimated to be approximately $5 billion. 19 All cost studies in the prebiologic era demonstrated increased economic burden among PsO patients in the United States and Canada, [20] [21] [22] [23] and all suggested that most PsO-related economic burden was attributed to moderate-to-severe patients.
Treatments for PsO vary across disease severity. For decades, immunosuppressants were the only pharmacological treatments for moderate-to-severe PsO. The introduction of biologics in recent years has significantly changed PsO treatment paradigms. Biologics are cost-effective in improving clinical outcomes, quality of life, and work productivity, compared with conventional therapies. 24, 25 The pathogenic targets of biologics can include proinflammatory cytokines that play an imperative role in the pathogenesis of PsA and Crohn's disease; cardiometabolic pathways (insulin resistance, lipid metabolism, and general body weight homeostasis); and atherogenesis. 7 Therefore, effective treatment of PsO with biologics may reduce medical resource utilization and costs over time. One recent study revealed significant reductions in all hospital resource use and costs in the year following initiation of biologics among patients with moderate-to-severe PsO. 26 Although the economic burden of PsO was examined during the prebiologics time, [20] [21] [22] 27 ,28 a study is needed to determine whether there remains a high economic and comorbidity burden among PsO patients since the introduction of biologics, particularly for moderate-to-severe PsO patients. Our study assessed the comorbidity burden, health care utilization, and costs associated with moderate-to-severe PsO patients compared with a demographically matched cohort without PsO or PsA.
■■ Methods Data Source
This is a retrospective study using data from the OptumHealth Reporting and Insights claims database from January 1, 2007, to March 31, 2012, which represents approximately 15.5 million privately insured individuals from 69 companies in a wide range of industries and occupations across the United States. Medical and pharmacy claims, as well as eligibility data are available for all beneficiaries for services provided. Enrollment/ eligibility records for each patient contain demographic information, including age, gender, and census region. Medical claims comprise information on inpatient and outpatient care, including the service date, type and place of service, provider type, International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes, and the Current Procedural Terminology (CPT) code. Pharmacy claims capture the National Drug Code (NDC) number, dispensing date, quantity of drug, and number of days supplied. Payment information is available at the claims level.
Medication use was measured by any medication filled and number of medications filled. All-cause and selected medications of interest, such as antidepressants, antidiabetic drugs, and cardiovascular drugs/antihypertensives (identified based on GPI codes; Appendix E, available in online article), were analyzed separately. All-cause health care utilization outcomes were categorized by inpatient visit (any visit, number of visits, and length of inpatient stay); emergency room (ER) visit (any visit and number of visits); and outpatient visit (any visit and number of visits). Claims for inpatient, ER, and outpatient services were identified from the database based on the place of service, type of service, and the CPT codes. All-cause health care costs and PsO-related costs (PsO treatment costs and PsO-related medical costs, calculated for moderate-to-severe PsO patients only) were calculated as reimbursed amounts from payers and were adjusted to 2012 U.S. dollars using the medical care component of the Consumer Price Index. 30 Total health care costs and each cost component (i.e., pharmacy costs and medical costs including inpatient, ER, outpatient, and other costs) were examined.
Statistical Analyses
Descriptive statistics were provided for all patient characteristics and outcomes. Continuous variables were summarized using means and standard deviations (SDs); categorical variables were described using frequency counts and percentages. Unadjusted values were compared between the matched PsO patients and controls using Wilcoxon signed-rank tests for continuous variables and McNemar's tests for binary variables.
Multivariate regression models were performed to assess the association between PsO and comorbidities, medication use, Patients with at least 12 months of continuous eligibility after a potential index date (a randomly selected date after the first diagnosis of PsO) n = 34,583
Patients aged between 18 to 64 years as of a potential index date n = 25,327
Patients with moderate-to-severe PsO, defined as having at least 1 nontopical systemic therapy (including biologics and nonbiologics) or phototherapy received during the 12-month study period n = 5,492
Moderate-to-severe PsO patients were matched to control candidates on a 1:1 ratio on age, gender, and geographic region N = 5,492 
FIGURE 1
Selection of Study Cohorts medical resource utilization, and health care costs, adjusting for demographics, index year, insurance type, other comorbid medical conditions, and modified CCI measured during the 12-month study period. Specifically, conditional logistic regressions were used to compare binary variables, including occurrence of comorbidities, any medication fill, and any medical service utilization. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated. Negative binomial regressions were used to compare count variables, including number of distinctive medications filled and the number of medical service visits. Generalized estimating equation (GEE) was used to account for correlation between matched pairs. Incidence rate ratios (IRRs) and 95% CIs were estimated. Two-part models with GEE were used to determine the adjusted cost differences between the matched cohorts. The first part was a logistic regression modeling the probability of having a nonzero cost, and the second part was a generalized linear regression estimating cost values with a gamma distribution and log link. 31 The bootstrap resampling method was used to estimate the adjusted mean cost differences between cohorts and associated P values. 32 All data analyses were conducted using SAS version 9.2 (SAS Institute, Carey, NC).
■■ Results
A total of 48,843 patients had at least 2 ICD-9-CM diagnoses of PsO on different dates between January 1, 2007, and March 31, 2012 ( Figure 1 ). The final sample comprised 5,492 moderateto-severe PsO patients who met all inclusion and exclusion criteria and included 5,492 pairs of moderate-to-severe PsO patients and their matched controls based on age, gender, and geographic region. Per study design, the PsO patients and controls had similar patient demographics with a mean age of 47.6 years and 44.5% being female ( 
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organizations. Compared with matched controls, PsO patients had higher modified CCI scores (0.26 vs. 0.13, P < 0.001) and increased burden in all other comorbid medical conditions assessed (all P < 0.01; Table 2 ).
The prevalence of all selected and common comorbidities was higher, and the risk of having almost all these comorbidities assessed was elevated among PsO patients during the 12-month study period, compared with controls (Table 3) . PsA was present among 22.1% of PsO patients. Excluding PsA, the most common comorbidities in PsO patients were related to metabolic syndrome, including hyperlipidemia (33.3% vs. 27.3%, adjusted OR [aOR] = 1.3), hypertension (32.8% vs. 23.5%, aOR = 1.6), and diabetes (15.8% vs. 9.7%, aOR = 1.7). Obesity, another condition related to metabolic syndrome, was observed in 4.8% of PsO patients, compared with 2.3% of controls (aOR = 1.9). Depression and anxiety affected 9.1% and 6.3% PsO patients, respectively (aOR = 1.7 and 1.4). PsO patients were also more likely to have rheumatic arthritis (aOR = 9.9), Crohn's disease/ulcerative colitis (aOR = 3.4), and other autoimmune diseases (aOR = 2.7), compared with controls. Additionally, PsO patients had an elevated risk of coronary heart disease (aOR = 1.5), cerebrovascular disease (aOR = 1.7), peripheral vascular disease (aOR = 1.6), skin cancer (aOR = 1.9) including nonmelanoma skin cancer (aOR = 2.1), and lymphoma (aOR = 22.7).
During the 12-month study period, 3,582 (65.2%) of the moderate-to-severe PsO patients used biologics; 1,502 (27.3%) used nonbiologic systemic therapies; and 906 (16.5%) used phototherapies (Table 4) . Patients who used any combination of these systemic PsO therapies were counted in more than 1 group. In addition, PsO patients were more likely to have any medication filled (98.8% vs. 76.6%, aOR = 27.5) and have selected medications of interest filled (57.8% vs. 42.8%, aOR = 1.9), including antidepressants (25.0% vs. 13.9%, aOR = 2.1), antidiabetic drugs (11.3% vs. 6.8%, aOR = 1.7), and cardiovascular drugs/antihypertensives (47.9% vs. 36.1%, aOR = 1.7; all P < 0.001). On average, PsO patients filled more distinct prescription medications (10.96 vs. [20] [21] [22] Using large claims databases, previous studies found that the annual incremental total cost for the overall PsO population ranged between $900 ($2,006 using 1998-2005 data) and $1,976 ($2,007 using 2003 data), 21, 22 while the annual incremental total health care costs for moderate-to-severe PsO patients were $7,084 (medical services: $3,167; medications: $3,917) higher than controls without PsO or PsA. 22 Using a more recent database, our incremental total costs were over 2.6 times that estimated by Yu et al. (2009) , with over 70% of the cost difference attributed to pharmacy. 22 Similar to estimates from Yu et al., our moderate-to-severe PsO patients were more likely to have inpatient admissions, ER visits, and outpatient visits than controls without PsO or PsA.
This study clearly showed an elevated risk for selected and common comorbidities among moderate-to-severe PsO patients, particularly for cardiometabolic diseases. The leading comorbidities in our moderate-to-severe sample were hyperlipidemia (33.3%) and hypertension (32.8%), which were slightly $2,421, ACD = $2,151), and other medical costs ($435 vs. $189, ACD = $194; all P < 0.001). During the 12-month study period, the moderate-to-severe PsO patients incurred an average of $13,731 PsO-related costs, a majority of which were attributed to treatment costs for systemic PsO therapies ($12,958) that included biologics, nonbiologics, and phototherapies (Table 5) .
■■ Discussion
Using a recent and large U.S. administrative claims database, this study assessed the comorbidity and economic burden of moderate-to-severe PsO in the biologic era. The findings demonstrated that moderate-to-severe PsO patients are associated with significantly higher prevalence of comorbidities; greater health care resource utilization, including medication use and medical service utilization; and higher health care costs, compared with controls without PsO or PsA.
Our findings were consistent with earlier PsO economic burden studies, including those before biologics were avail- 
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brovascular disease in the overall PsO population, compared with 50% and 70% in our moderate-to-severe PsO sample. 33 Besides cardiovascular and metabolic syndrome, moderateto-severe PsO patients face higher risks for other comorbidities. In our moderate-to-severe PsO sample, 22% were comorbid with PsA, which is comparable to the data in a 2001 U.S. survey with PsA reported in 18% moderate PsO patients and 56% in severe PsO patients. 34 Our study found increased risks of depression (aOR = 1.7) and autoimmune disorders such as higher than the prevalence among the overall PsO population reported in a previous study (27% for hyperlipidemia and 25% for hypertension). 9 Furthermore, Neimann et al. (2006) estimated a 62% higher adjusted odds for diabetes mellitus and 79% higher adjusted odds for obesity in patients with severe PsO, which is comparable to the 70% and 90% found in our study. 15 Another analysis using 2 large U.S. health plan databases during 2001-2002 reported a roughly 20% higher odds for coronary heart disease and 13%-18% higher odds for cere- 
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rheumatoid arthritis (aOR = 9.9) and Crohn's disease/ulcerative colitis (aOR = 3.4) among moderate-to-severe PsO patients. Our findings were consistent with those reported in a German case-control study (aOR = 1.49 for depression), 6 and a U.S. retrospective cohort study (aOR = 3.6 for rheumatoid arthritis, aOR = 1.5 for ulcerative colitis, and aOR = 1.8 for Crohn's disease). 35 Similarly, a higher risk for nonmelanoma skin cancer (aOR = 1.9) and lymphoma (aOR = 22.7) was found in our study, consistent with the findings in a U.S. national survey (relative risk = 1.7-2.2) and a large United Kingdom cohort study (adjust hazard ratio = 1.59 for lymphoma). 36, 37 The risks of comorbidities in our moderate-to-severe sample are generally higher than those reported for the overall PsO sample in the literature. Despite different study design and populations, the increasing trend could be explained by the positive relationship between severity of PsO and likelihood of these conditions. This study revealed that the economic and comorbidity burden of moderate-to-severe PsO remains high even with the availability of biologic treatments. Biologics may work on both symptoms commonly observed among PsO patients and other comorbidities by modifying the immune-inflammatory pathway. 7 Future studies comparing the health care utilization and costs between patients on biologics versus those on nonbiologic systemic therapies are warranted to further understand the economic impact of biologics.
The high economic burden identified in the current study demonstrates that unmet needs remain in this patient population. Treatment plans should reflect the severity of PsO and the need of care for comorbidities that include PsA, metaboliccardiovascular conditions, psychiatric disorders, autoimmune conditions, skin cancer, and lymphoma. More patient-centered care coordination through multispecialty PsO teams (e.g., dermatology, rheumatology, primary care, and endocrinology) is a priority area in research and practice to improve care for PsO.
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Limitations
This study has several limitations. First, it is a retrospective observational study that could be affected by unobserved differences between comparison cohorts. Second, classification bias may exist. Since comorbidities were identified using administrative ICD-9-CM codes, medical conditions might not be accurately captured in the data because of undercoding, upcoding, or miscoding. Another classification bias may arise from the identification of moderate-to-severe PsO patients using treatment claims. Due to lack of clinical measures of PsO severity (e.g., the Psoriasis Area and Severity Index) in the claims datasets, we used systemic treatments (pharmacologic or phototherapy) to define the moderate-to-severe PsO cohort. By definition, PsO patients would incur these treatments that did not apply to the control patients. However, treatment as a proxy of disease severity is commonly used in commercial claims database analyses for PsO studies. 22, 27 It is rare that moderate-to-severe PsO patients would not receive any of these treatments. Therefore, we do not expect substantial bias generated using this approach. Third, this study is from a payer perspective and may understate direct costs because patient out-of-pocket costs were not considered. Fourth, our study assessed only the direct health care costs associated with PsO. The costs associated with decrements in quality of life, lost productivity, and work absenteeism were not included in our analysis. Finally, generalization of the study findings to populations beyond the commercially insured patients should be done cautiously, since the Medicare and Medicaid populations may have different characteristics.
■■ Conclusions
Using updated data, this study indicates that moderate-tosevere PsO patients were more likely to have selected comorbidities and higher all-cause health care utilization and costs than PsO-and PsA-free controls. The incremental comorbidity and economic burdens associated with moderate-to-severe PsO highlight the need for more effective treatments.
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Study concept and design were created by Feldman, Zhao, Shi, and Tran. Data collection was performed by Shi, and all authors participated in data interpretation. The manuscript was written and revised by all the authors. Photochemotherapy (Goeckerman and/or PUVA) for severe photoresponsive dermatoses requiring at least 4 to 8 hours of care under direct supervision of the physician (includes application of medication and dressings) 96920
Moderate
Laser treatment for inflammatory skin disease (PsO); total area less than 250 sq cm 96921
Laser treatment for inflammatory skin disease (PsO); 250 sq cm to 500 sq cm 96922
Laser treatment for inflammatory skin disease (PsO); over 500 sq cm CPT = Current Procedural Terminology; PsO = psoriasis; sq cm = square centimeters. 
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